{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["41(11)"],"submitter":["Chin KM"],"funding":["Actelion Pharmaceuticals Ltd, a Johnson &amp; Johnson Company"],"pubmed_abstract":["<h4>Introduction</h4>Historically, patients recently (≤ 6 months) diagnosed with pulmonary arterial hypertension (PAH; incident) have had poorer survival than those with a longer (> 6 months) time from PAH diagnosis (prevalent). Despite guideline recommendations for initial combination therapy for most patients with PAH, many are initiated and maintained on monotherapy. Real-world evidence to evaluate the benefit of early combination treatment in newly-diagnosed patients is lacking.<h4>Methods</h4>Patients with PAH initiating combination therapy with the endothelin receptor antagonist macitentan and the phosphodiesterase-5 inhibitor tadalafil (M+T) were identified from the combined dataset of the US, multicenter OPUS (prospective, observational drug registry; NCT02126943) and OrPHeUS (retr"],"journal":["Advances in therapy"],"pagination":["4205-4227"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11480149"],"repository":["biostudies-literature"],"pubmed_title":["Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies."],"pmcid":["PMC11480149"],"pubmed_authors":["Senatore A","Ong R","Channick R","McLaughlin VV","MacDonald G","Martin N","Chin KM","Kim NH"],"additional_accession":[]},"is_claimable":false,"name":"Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies.","description":"<h4>Introduction</h4>Historically, patients recently (≤ 6 months) diagnosed with pulmonary arterial hypertension (PAH; incident) have had poorer survival than those with a longer (> 6 months) time from PAH diagnosis (prevalent). Despite guideline recommendations for initial combination therapy for most patients with PAH, many are initiated and maintained on monotherapy. Real-world evidence to evaluate the benefit of early combination treatment in newly-diagnosed patients is lacking.<h4>Methods</h4>Patients with PAH initiating combination therapy with the endothelin receptor antagonist macitentan and the phosphodiesterase-5 inhibitor tadalafil (M+T) were identified from the combined dataset of the US, multicenter OPUS (prospective, observational drug registry; NCT02126943) and OrPHeUS (retr","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-07-15T05:33:07.268Z","creation":"2025-04-04T19:38:08.868Z"},"accession":"S-EPMC11480149","cross_references":{"pubmed":["39316293"],"doi":["10.1007/s12325-024-02964-0"]}}